Synonyms for suicidality or Related words with suicidality

pocd              ptsd              schizophrenics              hypomania              mtbi              psychopathology              ideation              treatmentemergent              ponv              dysphoria              ymrs              comorbidity              symptons              schizophrenic              ideationcompared              dysthymia              attempters              endophenotype              madrs              sudep              neurobehavioral              impulsivity              neurocognitive              depressives              posthypoxic              symptomatologies              somnolence              somatization              panss              sleeplessness              tmjd              malingering              hypoactivity              anhedonic              catatonia              anhedonia              hypomagnesemia              hamd              motn              hrql              pdnv              nonconvulsive              subscale              migraineurs              subsyndromal              narcoleptic              neuroses              anaclitic              amnesias              hrsd             



Examples of "suicidality"
Exner and others have claimed that the Rorschach test is capable of detecting suicidality.
Mixed states are associated with greater levels of suicidality than non-mixed depression. Antidepressants may increase this risk.
& Blatt noted an association between the representation of transparent and cross-sectional images and suicidality, an observation subsequently supported by empirical investigation
The "Lifetime/Recent version allows practitioners to gather lifetime history of suicidality as well as any recent suicidal ideation and/or behavior." The "Since Last Visit version of the scale assesses suicidality since the patient’s last visit." The "Screener version of the C-SSRS is a truncated form of the Full Version" designed for "first responders, in ER settings and crisis call centers, for non-mental health users like teachers or clergy or in situations where frequent monitoring is required." The "Risk Assessment Page provides a checklist for protective and risk factors for suicidality."
Panic attacks; agitation or restlessness; irritability and aggression, anxiety, or depression; suicidality; insomnia and mania; altered mood; false and unusual sense of well-being.
In 2007 the FDA required all antidepressants to carry a black box warning stating that antidepressants may increase the risk of suicide in people younger than 25. This warning is based on statistical analyses conducted by two independent groups of FDA experts that found a 2-fold increase of the suicidal ideation and behavior in children and adolescents, and 1.5-fold increase of suicidality in the 18–24 age group. The suicidality was slightly decreased for those older than 24, and statistically significantly lower in the 65 and older group. This analysis was criticized by Donald Klein, who noted that suicidality, that is suicidal ideation and behavior, is not necessarily a good surrogate marker for completed suicide, and it is still possible that antidepressants may prevent actual suicide while increasing suicidality.
A study by Goodenow et al. (2006) was one of the first to examine which school-related factors were associated with lower rates of victimization and suicidality in this population. School related factors included the presence of LGB support groups and staff support as well as other school characteristics like student-to-teacher ratio. It was found that LGB support groups were associated with both low victimization and suicidality among LGB students. Results indicated that the existence of LGB support groups may have led to a decrease in suicidality through decreasing incidence of peer victimization as the association between LGB support groups and suicidality disappeared when victimization was controlled for. Yet as this study examined correlations, causality cannot be assumed. Student courts were associated with less victimization, and antibullying policies were associated with less suicidality, even when the effects of victimization and perceived support were taken into account. Lower levels of victimization and suicidality of LGB students was also associated with large school size and urban locale. These school-related factors have traditionally been associated with a generally safer school environment, yet it seems that factors that increase safety for the general population may not increase safety for LGB students.
This product is Turing Pharmaceuticals' intranasal formulation of ketamine. The company is working on the product for the treatment of suicidality.
Studies have shown that the use of antidepressants is correlated with an increased risk of suicidal behaviour and thinking (suicidality) in those aged under 25. This problem has been serious enough to warrant government intervention by the US Food and Drug Administration (FDA) to warn of the increased risk of suicidality during antidepressant treatment. According to the FDA, the heightened risk of suicidality is within the first one to two months of treatment. The National Institute for Health and Care Excellence (NICE) places the excess risk in the "early stages of treatment". A meta-analysis suggests that the relationship between antidepressant use and suicidal behavior or thoughts is age-dependent. Compared to placebo the use of antidepressants is associated with an increase in suicidal behavior or thoughts among those aged under 25 (OR=1.62). This increase in suicidality approaches that observed in children and adolescents. There is no effect or possibly a mild protective effect among those aged 25 to 64 (OR=0.79). Antidepressant treatment has a protective effect against suicidality among those aged 65 and over (OR=0.37).
There is an association between suicidality and physical health problems such as chronic pain, traumatic brain injury, cancer, kidney failure (requiring hemodialysis), HIV, and systemic lupus erythematosus. The diagnosis of cancer approximately doubles the subsequent risk of suicide. The prevalence of increased suicidality persisted after adjusting for depressive illness and alcohol abuse. In people with more than one medical condition the risk was particularly high. In Japan, health problems are listed as the primary justification for suicide.
The book calls for not only "more and better resources for at-risk LGBTQ youth, but also a transformation of the structures that maintain the epidemics of homelessness, suicidality, mental illness and addiction in this marginalized population."
Topiramate has been associated with a statistically significant increase in suicidality, and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500."
Peter Breggin asserted that there was an association between fluoxetine (Prozac) use and suicidal ideation. While his research group were investigating the effectiveness and side effects of the medication, Breggin noticed that only certain individuals responded to the medication with increased thoughts of suicide, and used the challenge-dechallenge-rechallenge protocol in an effort to verify the link. Given the low occurrence rate of suicidality, statistical testing was considered inappropriate. Other researchers have similarly suggested that the CDR is useful for researching the adverse effect of suicidality while taking fluoxetine, and Eli Lilly adopted the protocol rather than randomized controlled trials when testing for increased risk of suicide. In addition to suicidality, akathisia is a reaction to medication which is suggested as amendable to a CDR protocol.
A 2016 review of 70 clinical trials of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) including about 18,500 subjects and relied on clinical reports as well as the available data looked at four outcomes — death, suicidality, aggressive behaviour, and agitation — and found that while the data was insufficient to draw strong conclusions, adults taking these drugs did not appear to be at increased risk for any of the four outcomes, but that for children, the risks of suicidality and for aggression doubled. The authors expressed frustration with incomplete reporting and lack of access to data, and with some aspects of the clinical trial designs.
Like other antidepressants, paroxetine may increase the risk of suicidal thinking and behaviour in children and adolescents. The FDA conducted a statistical analysis of paroxetine clinical trials in children and adolescents in 2004, finding an increase in "suicidality" and ideation as compared to placebo; the trend for increased "suicidality" was observed in both trials for depression and for anxiety disorders. In 2015 a paper published in the BMJ that reanalysed the original case notes, argued that in Study 329, assessing paroxetine and imipramine against placebo in adolescents with depression, the incidence of suicidal behavior had been under-reported and efficacy exaggerated for paroxetine.
Mental health professionals and some other health professionals receive training in assessment and treatment of suicidality. Suicide hotlines are widely available for people seeking help. However, some people may be reluctant to discuss their suicidal thoughts, due to stigma, previous negative experiences, or other reasons.
According to the MHRA, the data provided "robust evidence" of a causal link between paroxetine and suicidality, and no evidence that paroxetine was effective in treating depression in children. Alasdair Breckenridge, chair of the MRHA at the time, said it caused "a very dramatic change in our thinking about Seroxat and children."
In the general population a weak (indirect) association appears to exist between suicidal behaviour and cannabis consumption in both psychotic and non-psychotic users, although it remains unclear whether regular cannabis use increases the risk of suicide. Cannabis use is a risk factor in suicidality, but suicide attempts are characterized by many additional risk factors including mood disorders, stress, personal problems and poor support.
There is tentative evidence that psychotherapy, specifically, dialectical behaviour therapy reduces suicidality in adolescents as well as in those with borderline personality disorder. It may also be useful in decreasing suicide attempts in adults at high risk. Evidence however has not found a decrease in completed suicides.
Other studies indicate that people that suffer from PTSD have chronically low levels of serotonin, which contributes to the commonly associated behavioral symptoms such as anxiety, ruminations, irritability, aggression, suicidality, and impulsivity. Serotonin also contributes to the stabilization of glucocorticoid production.